The clinical trials below are available in the specialty you selected. Choose a different specialty.

Phase II Prospective Study Evaluating the Role of Pemetrexed Plus Gemcitabine Chemotherapy for Chemo Naïve Select Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy
Patients will receive cisplatin plus gemcitabine or pemetrexed plus gemcitabine based on genomic characteristics of the tumor determined by biopsy. (REF# 4599)

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
All patients enrolled on this trial will receive dasatinib orally for six weeks then be reassessed. (REF# 8303)

Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemotherapy with Either Vinorelbine or Pemetrexed for the Adjuvant Treatment of Early Stage NSCLC in Patients Using Genomic Expression Profiles of Chemotherapy Sensitivity to Guide Therapy
Patients will receive vinorelbine plus cisplatin or pemetrexed plus cisplatin based on the genomic characteristics of the tumor as determined from the tumor biopsy. (REF# 0657)

Phase II Study Evaluating the Safety and Response to Neoadjuvant Dasatinib in Early Stage Non-Small Cell Lung Cancer (NSCLC)
Patients will be administered dasatinib orally for 21 days followed by surgical resection of the tumor. (REF# 1278)